Načítá se...
Passive immunotherapies targeting amyloid beta and tau oligomers in Alzheimer’s disease
Alzheimer’s disease (AD) is historically difficult to treat, in part due the inaccessible nature of brain pathology. Amyloid-β (Aβ) and tau proteins drive pathology by forming toxic oligomers that eventually deposit as insoluble amyloid plaques and neurofibrillary tangles. Recent clinical studies su...
Uloženo v:
| Vydáno v: | J Pharm Sci |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6937375/ https://ncbi.nlm.nih.gov/pubmed/31647950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2019.10.024 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|